Staying ahead of the competition is critical in every sector, particularly in the dynamic healthcare space, where a single ...
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
Johnson & Johnson has underperformed its large-cap healthcare peers and the S&P 500, with an -8% decline over the past year.
In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...